OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC

Background. Osteopontin (OPN) is associated with prognosis of patients with non-small-cell lung cancer (NSCLC). However, little is known about the association between OPN gene polymorphism and the chemotherapy response in NSCLC patients. Methods. A total of 497 patients with inoperable advanced stag...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yanzhang Hao, Jianwei Liu, Ping Wang, Feng Wang, Zeshun Yu, Mianli Li, Shaoshui Chen, Fangling Ning
Format:	Article
Language:	English
Published:	Wiley 2014-01-01
Series:	International Journal of Genomics
Online Access:	http://dx.doi.org/10.1155/2014/846142
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Relationship between PLR and Clinicopathological Characteristics of Patients with Advanced NSCLC and Its Predictive Value for the Efficacy of Chemotherapy and Prognosis
by: Jianming Zhao, et al.
Published: (2022-01-01)

Investigating the Role of Osteopontin (OPN) in the Progression of Breast, Prostate, Renal and Skin Cancers
by: Gautam Kundu, et al.
Published: (2025-01-01)

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification
by: Liang Zheng, et al.
Published: (2024-09-01)

Correlation between Post-Thaw Spermatozoa Quality of the Endangered Javan Banteng with OPN Gene Expression
by: Vincentia Trisna Yoelinda, et al.
Published: (2023-01-01)

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01)

Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer
by: Ke Zhu, et al.
Published: (2021-01-01)

Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis
by: Lauren Julia Brown, et al.
Published: (2025-01-01)

CircRNAs as Possible Potential Biomarkers for Breast Cancer Prognosis and Chemotherapy Response: A Comprehensive Study
by: Saba Mirzaei, et al.
Published: (2024-10-01)

The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC
by: Yifan Wang, et al.
Published: (2025-01-01)

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
by: Yang Zhang, et al.
Published: (2025-01-01)

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
by: Kyuhwan Kim, et al.
Published: (2025-02-01)

Carcinoembryonic antigen trajectory predicts pathological complete response in advanced gastric cancer after neoadjuvant chemotherapy
by: Yonghe Chen, et al.
Published: (2025-02-01)

Comparison of CRP, Procalcitonin, Neutrophil Counts, Eosinophil Counts, sTREM-1, and OPN between Pneumonic and Nonpneumonic Exacerbations in COPD Patients
by: Shan Mou, et al.
Published: (2022-01-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

TFCP2 Genetic Polymorphism Is Associated with Predisposition to and Transplant Prognosis of Hepatocellular Carcinoma
by: Zhikun Liu, et al.
Published: (2017-01-01)

Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
by: Jie Yang, et al.
Published: (2024-07-01)

Retracted: Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC
by: Emergency Medicine International
Published: (2024-01-01)

Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2025-01-01)

Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC
by: Helena Bote-de Cabo, MD, et al.
Published: (2025-03-01)

White Blood Cell and Granulocyte Counts Are Independent Predictive Factors for Prognosis of Advanced Pancreatic Caner
by: Lanyun Feng, et al.
Published: (2018-01-01)

Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC
by: Chao Liu, et al.
Published: (2025-02-01)

Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma
by: Francesca Huwyler, et al.
Published: (2024-12-01)

Differences in the genomic profiles of cell‐free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC
by: Zhen Wu, et al.
Published: (2019-03-01)

Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review
by: Jun Wang, et al.
Published: (2025-02-01)

Characterization of the genomic landscape in liver oligometastatic NSCLC
by: Rongxin Liao, et al.
Published: (2025-01-01)

Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma
by: Ming-Chun Ma, et al.
Published: (2014-01-01)

Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer
by: Ning Zhang, et al.
Published: (2025-01-01)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
by: Kinga Krukowska, et al.
Published: (2020-01-01)

TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology
by: Jing Lu, et al.
Published: (2025-03-01)

Characterization of tumor prognosis and sensitive chemotherapy drugs based on cuproptosis-related gene signature in ovarian cancer
by: Wei Tan, et al.
Published: (2025-01-01)

Drug response is related to NR3C1 and FAAH polymorphism in Chinese pediatric epilepsy patients
by: Hongli Wang, et al.
Published: (2025-02-01)

Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP
by: Min Kyeong Kim, et al.
Published: (2016-12-01)

Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC
by: Christian Rolfo, MD, PhD, et al.
Published: (2025-01-01)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
by: David P Carbone, et al.
Published: (2023-01-01)

Advanced Epithelioid Malignant Peripheral Nerve Sheath Tumor Showing Complete Response to Combined Surgery and Chemotherapy: A Case Report
by: Tomohiro Minagawa, et al.
Published: (2011-01-01)

FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma
by: Yu Ishizuya, et al.
Published: (2025-02-01)

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
by: Francesca Lucibello, MD, et al.
Published: (2025-01-01)

Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
by: L. I. Moskvicheva, et al.
Published: (2020-12-01)

Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient
by: Nedal Bukhari, et al.
Published: (2019-01-01)

Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis
by: Yakun Wang, et al.
Published: (2017-01-01)